Ryan Lynch Biography and Net Worth

Senior Vice President, Finance and Chief Accounting Officer of Crescent Biopharma

Ryan Lynch has served as Crescent’s treasurer, senior vice president of finance and chief accounting officer since December 2024. Prior to joining Crescent, Mr. Lynch served as vice president of finance at Kelonia Therapeutics, where he was responsible for overseeing the company’s finance and accounting functions. Prior to Kelonia, Mr. Lynch served as senior director, corporate controller at Morphic Therapeutic, a biopharmaceutical company and wholly owned subsidiary of Morphic Holding, a Nasdaq-listed biopharmaceutical company that was acquired by Eli Lilly and Company in 2024, where he was responsible for overseeing the company’s finance and accounting functions. Prior to joining Morphic, Mr. Lynch held positions of increasing responsibility at Concert Pharmaceuticals from 2014 to 2019, most recently serving as senior director, corporate controller. Mr. Lynch received an MS in accounting from the University of Massachusetts Amherst and a BBA in accounting from the University of Massachusetts Amherst. Mr. Lynch is a licensed certified public accountant in Massachusetts.

What is Ryan Lynch's net worth?: The estimated net worth of Ryan Lynch is at least $236.92 thousand as of June 22nd, 2026. Mr. Lynch owns 13,871 shares of Crescent Biopharma stock worth more than $236,917 as of July 1st. This net worth evaluation does not reflect any other assets that Mr. Lynch may own. Learn More about Ryan Lynch's net worth.
How do I contact Ryan Lynch?: The corporate mailing address for Mr. Lynch and other Crescent Biopharma executives is P.O. BOX 65, MONROVIA, MD 21770, US. Crescent Biopharma can also be reached via phone at 617-465-0586 and via email at [email protected] . Learn More on Ryan Lynch's contact information.
Has Ryan Lynch been buying or selling shares of Crescent Biopharma?: Ryan Lynch has not been actively trading shares of Crescent Biopharma over the course of the past ninety days. Most recently, Ryan Lynch sold 465 shares of the business's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $17.99, for a transaction totalling $8,365.35. Following the completion of the sale, the insider now directly owns 13,871 shares of the company's stock, valued at $249,539.29. Learn More on Ryan Lynch's trading history.
Who are Crescent Biopharma's active insiders?: Crescent Biopharma's insider roster includes Barbara Bispham (Insider), Joshua Brumm (CEO), Ellie Im (Chief Medical Officer), Ryan Lynch (Senior Vice President, Finance and Chief Accounting Officer), Jonathan McNeill (President and Chief Operating Officer), Jan Pinkas (Chief Scientific Officer), and Richard Scalzo (CFO). Learn More on Crescent Biopharma's active insiders.
Are insiders buying or selling shares of Crescent Biopharma?: During the last year, Crescent Biopharma insiders bought shares 1 times. They purchased a total of 1,360,000 shares worth more than $18,237,600.00. During the last year, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 68,156 shares worth more than $1,226,126.44. The most recent insider tranaction occured on June, 22nd when insider Ryan Lynch sold 465 shares worth more than $8,365.35. Insiders at Crescent Biopharma own 8.7% of the company. Learn More about insider trades at Crescent Biopharma.
Information on this page was last updated on 6/22/2026.

Ryan Lynch Insider Trading History at Crescent Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/22/2026	Sell	465	$17.99	$8,365.35	13,871

Ryan Lynch Buying and Selling Activity at Crescent Biopharma

Crescent Biopharma Company Overview

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Today's Range

Now: $17.08

$16.97

$18.52

50 Day Range

MA: $19.63

$16.99

$26.98

2 Week Range

Now: $17.08

$8.72

$27.41

Volume

179,598 shs

Average Volume

258,889 shs

Market Capitalization

$470.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16